The chromene derivative 4-Clpgc inhibits cell proliferation and induces apoptosis in the K562 cell line

  • Fatemeh Asgari
  • Roya MahinpourEmail author
  • Leila Moradi
  • Nooshin HaghighipourEmail author


Chronic myeloid leukemia (CML) is a malignant blood disease with a particular chromosomal aberration that is known as a common form of leukemia. The chromene family exhibits strong anti-cancer effects. Therefore, the effects of six members of the dihydropyrano [2,3-g] chromene family on cell toxicity and apoptosis induction in K562 cancer cells were investigated and compared with those of normal peripheral blood mononuclear cells (PBMCs). The K562 cells were cultured in the presence of the aforementioned chromene derivatives at concentrations of 40 to 200 μM for 24 to 72 h. The effects of these compounds on the growth and viability of the K562 cell line and PBMCs were studied through MTT assay. Furthermore, apoptosis induction was investigated using flow cytometry. Real-time PCR was used for relative quantification of BCL2, Bax, TP53 and BCR- ABL genes after 48 h of exposing K562 cells and PBMCs to 4-Clpgc. Based on the results, these chromene derivatives inhibited the growth of K562 cells. According to the obtained data, 4-Clpgc was the strongest compound with IC50 values of 102 ± 1.6 μM and 143 ± 9.41 μM in K562 cells and PBMCs, while pgc was the weakest one with IC50 levels of 278 ± 2.7 μM and 366 ± 47 μM in K562 cells and PBMCs (after 72 h), respectively. The results demonstrated that the apoptotic cell percentage in the control group increased from 6.09% to 84.10% and 17.2% to 20.06% in K562 cells and PBMCs after 48 h of treatment, respectively. Moreover, 4-Clpgc treatment increased the expression of Bax and TP53 genes by 42.74 and 35.88 folds in K562 cells and 9.60 and 7.75 folds in PBMCs, respectively. On the other hand, the expression of BCL2 was reduced by 1.47 and 1.38 folds in K562 cells and PBMCs, respectively. These compounds were associated with less toxic effects on normal cells, compared to the cancer cells. In conclusion, these derivatives can be considered as appropriate candidates for leukemia treatment.


Chronic myeloid leukemia Dihydropyrano [2,3-g] chromene Apoptosis BCL2 Bax BCR-ABL 



The authors would like to thank faculty of chemistry university of Kashan for synthesizing materials used in project and Pasteur Institute of Iran for providing the facilities and financial support to conduct this research project.


  1. Adams JM, Cory S (1998) The Bcl-2 protein family: arbiters of cell survival. Science 281:1322–1326CrossRefGoogle Scholar
  2. Calabretta B, Perrotti D (2004) The biology of CML blast crisis Blood 103:4010–4022Google Scholar
  3. Cortes JE et al. (2012) PACE: a pivotal phase II trial of ponatinib in patients with CML and Ph+ ALL resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation. American Society of Clinical Oncology,Google Scholar
  4. Deininger MW, Goldman JM, Melo JV (2000) The molecular biology of chronic myeloid leukemia. Blood 96:3343–3356Google Scholar
  5. Domingos PM, Steller H (2007) Pathways regulating apoptosis during patterning and development. Curr Opin Genet Dev 17:294–299CrossRefGoogle Scholar
  6. Dosik GM, Barlogie B, Johnston D, Mellard D, Freireich EJ (1981) Dose-dependent suppression of DNA synthesis in vitro as a predictor of clinical response in adult acute myeloblastic leukemia. Eur J Cancer 17:549–555CrossRefGoogle Scholar
  7. Elmore S (2007) Apoptosis: a review of programmed cell death. Toxicol Pathol 35:495–516CrossRefGoogle Scholar
  8. Emmadi NR, Atmakur K, Chityal GK, Pombala S, Nanubolu JB (2012) Synthesis and cytotoxicity evaluation of highly functionalized pyranochromenes and pyranopyrans. Bioorg Med Chem Lett 22:7261–7264CrossRefGoogle Scholar
  9. Fan W (1999) Possible mechanisms of paclitaxel-induced apoptosis. Biochem Pharmacol 57:1215–1221CrossRefGoogle Scholar
  10. Ghasemian M, Mahdavi M, Zare P, Feizi MAH (2015) Spiroquinazolinone-induced cytotoxicity and apoptosis in K562 human leukemia cells: alteration in expression levels of Bcl-2 and Bax. J Toxicol Sci 40:115–126CrossRefGoogle Scholar
  11. Gourdeau H et al (2004) Antivascular and antitumor evaluation of 2-amino-4-(3-bromo-4, 5-dimethoxy-phenyl)-3-cyano-4H-chromenes, a novel series of anticancer agents. Mol Cancer Ther 3:1375–1384Google Scholar
  12. Heidary Alizadeh B et al (2010) Synthesis and cytotoxic activity of novel 9-[hydroxy (substitutedphenyl) methyl]-2, 2-dimethyl-2, 3, 8, 9-tetrahydro-4h, 10h-pyrano [2, 3-f] chromene-4, 10-diones. Iran J Chem Chem Eng 29:189–196Google Scholar
  13. Ismail N, Pihie AHL, Nallapan M (2005) Xanthorrhizol induces apoptosis via the up-regulation of bax and p53 in HeLa cells. Anticancer Res 25:2221–2227Google Scholar
  14. JC, R (1998) Bcl-2 family protein oncogenes 17:3225–3236Google Scholar
  15. Jiang H, Hou CH, Zhang SB, Xie HY, Zhou WY, Jin QH, Cheng XD, Qian RL, Zhang XJ (2007) Matrine upregulates the cell cycle protein E2F-1 and triggers apoptosis via the mitochondrial pathway in K562 cells. Eur J Pharmacol 559:98–108CrossRefGoogle Scholar
  16. Kasibhatla S et al (2004) Discovery and mechanism of action of a novel series of apoptosis inducers with potential vascular targeting activity. Mol Cancer Ther 3:1365–1374Google Scholar
  17. Keerthy HK, Garg M, Mohan CD, Madan V, Kanojia D, Shobith R, Nanjundaswamy S, Mason DJ, Bender A, Basappa, Rangappa KS, Koeffler HP (2014) Synthesis and characterization of novel 2-amino-chromene-nitriles that target Bcl-2 in acute myeloid leukemia cell lines. PLoS One 9:e107118CrossRefGoogle Scholar
  18. Kemnitzer W, Jiang S, Wang Y, Kasibhatla S, Crogan-Grundy C, Bubenik M, Labrecque D, Denis R, Lamothe S, Attardo G, Gourdeau H, Tseng B, Drewe J, Cai SX (2008) Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell-and caspase-based HTS assay. Part 5: modifications of the 2-and 3-positions. Bioorg Med Chem Lett 18:603–607CrossRefGoogle Scholar
  19. Kerr JF, Winterford CM, Harmon BV (1994) Apoptosis. Its significance in cancer and cancer therapy. Cancer 73:2013–2026CrossRefGoogle Scholar
  20. Lebedeva IV, Su Z-Z, Sarkar D, Fisher PB (2003) Restoring apoptosis as a strategy for cancer gene therapy: focus on p53 and mda-7. In: Seminars in cancer biology, vol 2. Elsevier, pp 169–178Google Scholar
  21. Mo S, Wang S, Zhou G, Yang Y, Li Y, Chen X, Shi J (2004) Phelligridins C− F: cytotoxic Pyrano [4, 3-c][2] benzopyran-1, 6-dione and Furo [3, 2-c] pyran-4-one derivatives from the fungus Phellinus i gniarius. J Nat Prod 67:823–828CrossRefGoogle Scholar
  22. Mohammadi Ziarani G, Badiei A, Azizi M, Zarabadi P (2011) Synthesis of 3, 4-dihydropyrano [c] chromene derivatives using sulfonic acid functionalized silica (SiO2PrSO3H). Iran J Chem Chem Eng 30:59–65Google Scholar
  23. Moosavi MA, Yazdanparast R, Lotfi A (2007) ERK1/2 inactivation and p38 MAPK-dependent caspase activation during guanosine 5′-triphosphate-mediated terminal erythroid differentiation of K562 cells. Int J Biochem Cell Biol 39:1685–1697CrossRefGoogle Scholar
  24. Moradi L, Sadegh MA (2017) Sodium saccharin as an effective catalyst for rapid one-pot pseudo-five component synthesis of Dihydropyrano [2, 3-g] chromenes under microwave irradiation. Acta Chim Slov 64:506–512CrossRefGoogle Scholar
  25. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55–63CrossRefGoogle Scholar
  26. Plati J, Bucur O, Khosravi-Far R (2011) Apoptotic cell signaling in cancer progression and therapy. Integr Biol 3:279–296CrossRefGoogle Scholar
  27. Rahimi R, Mahdavi M, Pejman S, Zare P, Balalaei S (2015) Inhibition of cell proliferation and induction of apoptosis in K562 human leukemia cells by the derivative (3-NpC) from dihydro-pyranochromenes family. Acta Biochim Pol 62:83–88CrossRefGoogle Scholar
  28. Sakamoto S, Kyprianou N (2010) Targeting anoikis resistance in prostate cancer metastasis. Mol Asp Med 31:205–214CrossRefGoogle Scholar
  29. Schmittgen TD, Livak KJ (2008) Analyzing real-time PCR data by the comparative C T method. Nat Protoc 3:1101–1108CrossRefGoogle Scholar
  30. Sun Y, Liu M, Yang B, Lu J, Li B (2008) Inhibition of laryngeal cancer cell invasion and growth with lentiviral-vector delivered short hairpin RNA targeting human MMP-9 gene. Cancer Investig 26:984–989CrossRefGoogle Scholar
  31. Taylor RC, Cullen SP, Martin SJ (2008) Apoptosis: controlled demolition at the cellular level. Nat Rev Mol Cell Biol 9:231–241CrossRefGoogle Scholar
  32. Teijido O, Dejean L (2010) Upregulation of Bcl2 inhibits apoptosis-driven BAX insertion but favors BAX relocalization in mitochondria. FEBS Lett 584:3305–3310CrossRefGoogle Scholar
  33. Thomas N, Zachariah SM (2013) Pharmacological activities of chromene derivatives: an overview. Asian J Pharm Clin Res 6:11–15Google Scholar
  34. Tzifi F, Economopoulou C, Gourgiotis D, Ardavanis A, Papageorgiou S, Scorilas A (2012) The role of BCL2 family of apoptosis regulator proteins in acute and chronic leukemias advances in hematology 2012Google Scholar
  35. Van Haaften RI, Evelo CT, Haenen GR, Bast A (2001) No reduction of α-tocopherol quinone by glutathione in rat liver microsomes. Biochem Pharmacol 61:715–719CrossRefGoogle Scholar
  36. Vosooghi M et al (2010) Synthesis and cytotoxic activity of some 2-amino-4-aryl-3-cyano-7-(dimethylamino)-4H-chromenes. Res Pharm Sci 5:9Google Scholar
  37. Ye Y-X, Zhou J, Zhou YH, Zhou Y, Song XB, Wang J, Lin L, Ying BW, Lu XJ (2014) Clinical significance of BCR-ABL fusion gene subtypes in chronic myelogenous and acute lymphoblastic leukemias. Asian Pac J Cancer Prev 15:9961–9966CrossRefGoogle Scholar

Copyright information

© The International CCN Society 2019

Authors and Affiliations

  1. 1.Department of Cellular and Molecular Biology, Faculty of ChemistryUniversity of KashanKashanIran
  2. 2.Department of Organic Chemistry, Faculty of ChemistryUniversity of KashanKashanIran
  3. 3.National Cell Bank of IranPasteur Institute of IranTehranIran

Personalised recommendations